Medtronic (MDT) News Today

Medtronic PLC (NYSE: MDT) is receiving mixed investor signals. Strong cardiovascular growth, an improved fiscal 2027 outlook and attractive dividend characteristics support the stock, while questions about the sustainability of growth, margin pressure and the planned diabetes-business exit may be limiting enthusiasm.

• Positive Sentiment: Medtronic reported a strong fiscal 2027 first quarter, with revenue of approximately $9.8 billion, organic growth of 13.7% and adjusted EPS of $1.45, exceeding analyst expectations. Cardiovascular products were the key growth driver, particularly heart devices. Medtronic’s Heart Devices Are Suddenly Outgrowing The Rest Of Med-Tech
• Positive Sentiment: Management raised its fiscal 2027 organic-revenue-growth outlook and increased the lower end of its adjusted earnings range following the quarterly beat. The improved guidance signals confidence that demand for cardiovascular devices can continue. Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum
• Positive Sentiment: Income-focused investors continue to view MDT favorably because of its roughly 3% dividend yield and 49 consecutive annual dividend increases. Medtronic is potentially about two years away from qualifying as a Dividend King, which could support demand for the shares. Medtronic Is on the Cusp of Becoming a Dividend King
• Neutral Sentiment: Jim Cramer described Medtronic as a “quandary”: the company is producing an unexpectedly strong growth rebound, but investors are also evaluating its planned exit from the diabetes business and the implications for its long-term portfolio. Jim Cramer Calls Medtronic a Quandary
• Negative Sentiment: Investors remain concerned that the quarter benefited from an extra selling week, which contributed roughly $570 million of revenue. Margin pressure, competition and uncertainty over whether cardiovascular momentum will persist could temper the positive reaction to the raised outlook. Medtronic Raised its Outlook as Heart Devices Accelerate